Congrats sarah_TO!! You should be so proud of yourself. 🎉

Clinical perspective on 2026 payer coverage update GLP-1:

I have managed roughly 300 patients on GLP-1 therapy and this topic comes up frequently. What the data shows — and what I see in practice — is that the medication works best as part of a comprehensive approach.

For this specific question, I would recommend: getting comprehensive baseline labs first.

pam_columbus said:

You should be so proud of yourself

I respect pam_columbus perspective but I think this oversimplifies things a bit. Re: 2026 payer coverage update — the subgroup analyses show meaningful heterogeneity.

I am not saying pam_columbus wrong entirely — just that the picture is more nuanced than a blanket statement. The STEP data specifically shows dose-dependent variation.

Exactly this. My pharmacist said the same thing about 2026 payer coverage.

Want to share my personal experience related to 2026 payer coverage update since I think it might help others in a similar situation.

I started my GLP-1 journey in March 2025 at 286 lbs with metabolic syndrome. My telehealth provider prescribed semaglutide 0.25mg to start.

Now, 18 months later: I am down 51 lbs, my labs have normalized, and my sleep apnea has improved dramatically. The 2026 payer coverage aspect specifically was something that made a big difference in my journey.

This forum was my go-to resource throughout.